22:14:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-08 X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 Kvartalsrapport 2024-Q1
2024-05-07 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-30 X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-24 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-17 Bokslutskommuniké 2019
2019-10-31 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-04 Årsstämma 2019
2019-05-23 X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito specialiserar sig på medicinsk teknik för digital patologi. Bolaget strävar efter att förbättra vävnadsdiagnostiken med sin patenterade teknologi baserad på uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
2023-12-08 08:00:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Today, December 8, 2023, is the last day for trading with unit rights in Lumito AB:s (publ) ("Lumito" or the "Company") issue of units consisting of warrants of series TO5 and TO6 (the "Issue"), which the board of directors resolved on November 10, 2023 (changes to the terms and conditions for the Issue were resolved and announced on November 17, 2023). Unit rights that are not sold or not exercised for subscription will expire without value.

The Issue summarized:

Subscription period: November 29, 2023 – December 13, 2023.

Trading with unit rights: November 29, 2023 – December 8, 2023.

Preferential right: For each (1) share held on the record date of November 27, 2023, one (1) unit right was granted, and forty-eight (48) unit rights entitle the subscription of one (1) unit.

Unit: One (1) unit consists of four (4) warrants of series TO5 and four (4) warrants of series TO6.

Subscription price: The subscription price amounts to SEK 0.01 per unit, corresponding to SEK 0.00125 per warrant.

Issue volume: In the event of full subscription in the Issue, the Company will receive approximately SEK 43 thousand before issue costs. Upon full exercise of all warrants of series TO5, the Company can receive an additional maximum amount of approximately SEK 41.3 million before issue costs. Upon full exercise of all warrants of series TO6, the Company can receive an additional maximum amount of approximately SEK 48.2 million before issue costs.

Advisers
Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor Lumito in connection with the Issue.